50 units of cord blood released for transplantation

When a baby is about to be born and his parents make the decision to conserve the umbilical cord blood with Vita 34, they know that they have a medicine in their hands to treat him if he ever needs it. Because in our laboratory we don't just freeze the baby's umbilical cord blood. We obtain, process and store it so that it has therapeutic properties.

That is why the German health authorities certify that the cord blood we keep is a medicine

And under this premise, a total of fifty families have been able to use the cord blood that they had preserved in our laboratory since 2004 . We have released the last three units for transplantation this year.

These stem cells have been used to treat cerebral palsy, autism, and in regenerative medicine.

In all three cases the blood has been released for own use in patients from Georgia, Romania and Ukraine.

The experience of a large private bank

Being the private bank that has released the most umbilical cord blood units is a guarantee of experience and professionalism. And not only that: it is the most concrete practical evidence of the usefulness of the stem cells that we conserve and of the quality of our processes. Vita 34 is licensed for all types of medical applications.

Diseases treated with stem cells

Today there are already standard treatments with this type of cells, both at the autologous level (with the own blood) and allogeneic (with blood from a donor). There are also many ongoing studies with cord blood cells in the treatment of very common diseases. This is the case of diabetes or Parkinson's, in cardiovascular, digestive, musculoskeletal and autoimmune diseases.

Next, the diseases that can be treated with autologous and / or allogeneic transplants, as well as other diseases that are in the experimental phase. Within this last group we find some pathologies that despite being classified as “experimentation”, their use is increasingly accepted in clinical practice.

DISEASES THAT CAN BE TREATED BY AUTOLOGOUS TRANSPLANTATION ( own )

CURRENT STANDARD TREATMENTS

Acute and chronic leukemias ¹

• Acute lymphoblastic leukemia (ALL)
• Acute myeloid leukemia (AML)
• Acute biphenotypic leukemia (BAL)
• Acute undifferentiated leukemia
• Chronic Lymphocytic Leukemia (CLL)

Lymphomas ¹

• Hodgkin lymphoma
• Non-Hodgkin's lymphoma

Blood cell proliferation disorders ¹

• Aplastic anemia
• Multiple myeloma
• Plasma cell leukemia
• Waldenstrom's macroglobulinemia (MW)

Other types of cancer ¹

• Neuroblastoma
• Medulloblastoma

TREATMENTS IN THE CLINICAL TRIAL PHASE

Autoimmune diseases

• Type I diabetes ^3,4
• Systemic lupus erythematosus ⁶
• Scleroderma
• Multiple sclerosis (MS) ⁶

Nerve cell repair

• Amyotrophic lateral sclerosis (ALS) ⁹
• Alzheimer's disease ⁹
• Parkinson's disease ^9,10
• Huntington's disease ^1.9
• Spinal cord damage ⁹

Transplants in cancerous tumors ¹

• Ewing's sarcoma ¹

Miscellaneous

• Vascular diseases ⁸
• Crohn's disease ⁶
• Repair of cardiac tissue after a heart attack ¹¹

Transplants diseases of the system. central nervous

• Cerebral palsy ⁵
• Autism

DISEASES THAT CAN BE TREATED BY ALLOGENIC TRANSPLANTATION ( donor )

CURRENT STANDARD TREATMENTS

Acute and chronic leukemias ¹

• Acute lymphoblastic leukemia (ALL)
• Acute myeloid leukemia (AML)
• Acute biphenotypic leukemia (BAL)
• Acute undifferentiated leukemia
• Chronic Lymphocytic Leukemia (CLL)
• CML chronic myeloid leukemia)
• Juvenile Chronic Myeloid Leukemia (JCML)
• Juvenile myelomonocytic leukemia (JMML)

Lymphomas ¹

• Hodgkin lymphoma
• Non-Hodgkin's lymphoma

Bone marrow cancer ¹

• Multiple myeloma
• Plasma cell leukemia
• Waldenstrom's macroglobulinemia (MW)

Other types of cancer ¹

• Retinoblastoma

Myelodysplastic syndromes ¹

• Refractory anemia
• Refractory anemia with ring sideroblasts (RARS)
• Refractory anemia with excess blasts (RAEB)
• Refractory anemia with excess blasts in transformation (RAEB-T)
• Chronic myelomonocytic leukemia (CMML)

Syst. Immune hereditary ^1,2

• Severe combined immunodeficiency (SCID) with adenosine deaminase deficiency (ADA-SCID) ¹
• SCID linked to chromosome X ¹
• SCID with absence of T and B lymphocytes ¹
• SCID with absence of lymphocyte. T and lympho. B normal ¹
• Omenn syndrome ¹
• Kostmann syndrome ¹
• Myelocatexis ¹
• Ataxia-telangiectasia ¹
• Common variable immunodeficiency ¹
• DiGeorge syndrome ¹
• Leukocyte adhesion deficiency ¹
• X- ^1- linked lymphoproliferative disorders
• Wiskott-Aldrich syndrome ¹

Blood cell proliferation disorders ¹

• Aplastic anemia
• Paroxysmal nocturnal hemoglobinuria (PNH)
• Glanzmann thrombocytopenia

Myeloproliferative disorders ¹

• Acute myelofibrosis
• Agnogenic myeloid metaplasm
• Polycythemia vera
• Essential or primary thrombocythemia

Phagocyte disorders ¹

• Chediak-Higashi syndrome
• Chronic granulomatous disease
• Actin deficiency in neutrophils
• Reticular dysgenesis

Hemoglobinopathies ¹

Inherited metabolic disorders ¹

• Mucopolysaccharidosis (MPS)

- Hurler syndrome (MPS-IH)

- Maroteaux-Lamy syndrome (MPS-VI)

- Sly syndrome (beta-glucuronidase deficiency) (MPS-VII)

• Leukodystrophies

- Adrenoleukodystrophy (ALD)

- Krabbe disease

- Metachromatic leukodystrophy (LDM)

• Lysosomal storage diseases

- Gaucher disease

• Other inherited disorders

- Osteopetrosis

Inherited red blood cell abnormalities ¹

• Beta-thalassemia major
• Blackfan-Diamond anemia
• Pure red series aplasia
• Fanconi anemia
• Congenital dyserythropoietic anemia
• Sickle cell disease
• Cartilage-hair hypoplasia syndrome ^1,2
• Shwachman-Diamond ^1,2 syndrome

EXPERIMENTAL MODELS IN DEVELOPMENT, COMMON FOR AUTOLOGOUS AND / OR ALLOGENIC TRANSPLANTS

Autoimmune / Immune Diseases

• Juvenile arthritis ³
• Rheumatoid arthritis ³
• Juvenile dermatomyositis ³
• Scleroderma ³

Immune Diseases

• Systemic lupus erythematosus ⁶
• Multiple sclerosis (MS) ⁶

Nerve cell diseases

• Amyotrophic lateral sclerosis (ALS) ^{9, 19,20}
• Alzheimer's disease ⁹
• Parkinson's disease ^9,10,32
• Huntington's disease ^1.9
• Spinal cord damage ⁹
• Vascular diseases ⁸
• Crohn's disease ⁶
• Premature brain damage, hypoxia ischemia ^35,36
• Brain injuries / neurodegenerative disorders ^37,46
• Cerebral palsy ^5.33.41
• Autism ^38,39,40
• Traumatic brain injury ^34.46

Cell proliferation disorders ¹

• Familial erythrophagocytic lymphohistiocytosis
• Hemophagocytosis
• Langerhans cell histiocytosis (LCH)
• Transplants in cancerous tumors ¹

- Renal cell carcinoma ¹

- Ewing's sarcoma ¹

Regenerative Medicine

• Type I and type II diabetes mellitus ^14,15
• Hepatic cirrhosis / Hepatic regeneration ^16,17
• Ulcerative colitis / inflammatory bowel disease ¹⁸
• Diabetic foot ulcers ^21,22
• Epidermolysis bullosa ^23.24
• Covid-19 ^43,44,45

Cardiovascular diseases

• Repair of cardiac tissue after a heart attack ¹¹
• Cardiovascular diseases ^{26,26,27,28,29,30,31,42}

Stem Cell Gene Therapy

• Fanconi anemia ⁷
• Tissue repair ¹²
• Muscle tissue repair ¹³

Bibliographic references:

1.E. Carreras, M. Rovira, C. Martínez. Hemopoietic Transplant Manual 2010, 4th edition. Editorial Antares.

2.Antoine C, Müller S, et al. Long term survival and transplantation of hemopoietic stem cells for immunodeficiency: report of the European experience 1968-99. Lancet 2003.

3. Michael Haller, Clive Wasserfall; Kieran McGrail; Miriam Cintron et al. Autologous Umbilical Cord Blood Transfusion in very young children with Type 1 Diabetes. Diabetes care; Nov 2009; 32, 11; ProQuest Helath and Medical complete. Page 2041.

4. www.clinicaltrials.gov .

5.J. Sun, J. Allison, et al. Differences in quality between privately and publicly banked umbilical cord blood units: a pilot study of autologous cord blood infusion in children with acquired neurologic disorders. Transfusion. Volume 50, Sep 2010. Page 1980.

6.Farge D, Labopin M, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years of experience from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. Feb 2010.

7. Baume C. Parchuting in the epigenome: the biology of gene vector insertion profi les in the context of clinical trials. EMBO Molecular Medicine 2011 February: Volume 3 page 75-77.

8.GP Fadini, C. Agostini, et al. Autologous stem cell theraphy for peripheral arterial disease. Meta-analysis and systematic review of the literature. Atherosclerosis 2009.

9.Wan-Zhang Yang, Yung Zhang et al. Safety evaluation of allogeneic umbilical cord blood mononuclear cell therapy for degenerative conditions. Journal of translational medicine 2010, 8:75.

10.A. Meyer, M. Maisel et al. Restorative approaches in Parkinson's Disease: which cell type wins the race? Journal of neurologica sciences 2009.

11.JM Hare, JH Traverse et al. A randomized, double-blind, placebo-controlled, dose escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. Journal of the American College of Cardiology. Vol. 54, No. 24, 2009.

12. David T. Harris. Non-haematological uses of cord blood stem cells. British Journal of Haematology 2009, 147, 177-184.

13.T. Jazedje, M. Secco et al. Stem cells from umbilical cord blood do have myogenic potential, with and without defferentiation induction in vitro. Journal of translational medicine, January 2009, 7: 6.

14.J Gan Y Wang; Stem cell transplantation for the treatment of patients with type 1 diabetes mellitus: A meta-analysis 2018.

15.DH Kassem, MM Kamal; Therapeutic effi cacy of umbilical cord-derived stem cells for diabetes mellitus: a meta-analysis study 2020.

16.Sang W, Lv B, Li K, Lu Y; Therapeutic effi cacy and safety of umbilical cord mesenchymal stem cell transplantation for liver cirrhosis in Chinese population: A meta-analysis; 2018 Jun.

17.I Anwar, UA Ashfaq; Therapeutic Potential of Umbilical Cord Stem Cells for Liver Regeneration 2020.

18. K Peng, X Qian, Z Huang; Umbilical cord blood transplantation corrects very early-onset inflammatory bowel disease in Chinese patients with IL10RA 2018-associated immunodeficiency.

19. Garbuzova-Davis S, Ehrhart J, Sanberg PR .; Cord blood as a potential therapeutic for amyotrophic lateral sclerosis 2017.

20. To Mehdipour, To Ebrahimi; The potential of umbilical cord derived mesenchymal stem cells in the treatment of multiple sclerosis; 2019 Nov.

21. P Volpe, D Marcuccio; Efficacy of Umbilical Cord Blood Platelet Gel Application to Improve Diabetic Foot Ulcer Healing After Lower Extremity Revascularization 2017.

22. N Çil, EO Oğuz; Effects of umbilical cord blood stem cells on diabetic foot injury healing factors; 2017.

23. G Tadini, S Guez; Preliminary evaluation of umbilical cord blood platelet gel for skin treatment. lesions in children with dystrophic epidermolysis bullosa; 2015.

24. Sang Eun Lee, Seung-Ju Lee; Intravenous treatment with allogeneic umbilical cord blood derived mesenchymal stem cells in patients with recessive dystrophic epidermolysis bullosa; 2021.

25. N Gurusamy, A Alsayari; Adult Stem Cells for Regenerative Therapy; 2018.

26. S Roura, C Gálvez-Montón; Mesenchymal Stem Cells for Cardiac Repair: Are Actors Ready for the Clinical Scenario?; 2017.

27. S Kashinath Medhekar, V Suresh Shende; Recent Advances in Stem Cells: Umbilical Cord Blood and Induced Pluripotent Stem Cells for Cardiac Regeneration: A Review; 2016.

28. N Hashemi Goradel, F Ghiyami‐ Hour; Stem Cell Therapy: A New Therapeutic Option for Cardiovascular Diseases; 2017.

29. P Müllera, H Lemckea Stem C

• By Secuvita
• 04/10/2021
• transplantation, blood, umbilical cord blood